Efficacy and safety of interferon-α2b spray in the treatment of hand, foot, and mouth disease: a multicenter, randomized, double-blind trial
Autor: | Kaichun Lin, Hongjiao Wang, Xia Xue, Jian Zhou, Chan Xia, Hailong Lin, Leting Huang |
---|---|
Rok vydání: | 2016 |
Předmět: |
Male
0301 basic medicine medicine.medical_specialty media_common.quotation_subject Interferon alpha-2 Biology Placebo medicine.disease_cause Antiviral Agents Placebos 03 medical and health sciences 0302 clinical medicine Medical microbiology Double-Blind Method Virology Internal medicine medicine Humans 030212 general & internal medicine Adverse effect media_common Aerosols Infant Interferon-alpha Appetite General Medicine Rash Recombinant Proteins Clinical trial Treatment Outcome 030104 developmental biology Child Preschool Enterovirus Female medicine.symptom Hand Foot and Mouth Disease Foot (unit) |
Zdroj: | Archives of Virology. 161:3073-3080 |
ISSN: | 1432-8798 0304-8608 |
DOI: | 10.1007/s00705-016-3012-7 |
Popis: | Hand, foot, and mouth disease (HFMD) is a common infectious enterovirus disease, occurring mostly in infants and children younger than 7 years with potentially fatal complications. Therefore, we evaluated the clinical efficacy and safety of recombinant human interferon (IFN)-α2b spray for treating mild HFMD in 400 patients in a randomized, open, controlled clinical trial. The patients were randomized to the IFN-α2b spray and placebo groups, and their temperature, skin rash, oral lesions, and appetite were monitored, while pathogen levels and safety were evaluated with a 7-day follow-up. The mean age of the patients was 20.1 ± 10.2 months. The median duration of fever, oral ulcers or vesicles (or both), and skin rash in addition to median time to regain appetite in the IFN-α2b spray group were shorter than they were in the placebo group. The number of virus-positive cases differed statistically between the two groups for the three follow-up detections. Additionally, the incidences of adverse events (AEs) and severe AEs (SAEs) were not significantly different between the two groups, and the SAEs were evidently unrelated to the IFN-α2b spray or placebo. Therefore, the IFN-α2b spray is suitable for topical treatment of HFMD, and it rapidly relieved fever, promoted oral lesions and subsidence of rash, enhanced appetite, promoted disease recovery, and was safe for application. |
Databáze: | OpenAIRE |
Externí odkaz: |